Publication
  • ERA •
  • 4 June, 2026 •
  • •

Decreasing rates of injection site reactions over time: Long-term outcomes across multiple indications support pegcetacoplan for C3G/primary IC-MPGN

Nabil Melhem, Antonio Mastrangelo, Daniel Zecher, Abdallah S Geara, Carla M Nester, Sheena Patel, Liza Alkhori Franzén, Andrew Carrel, Carlos de Castro, Daniel P Gale, Richard J. Kelly

Publication
  • ASH •
  • 8 December, 2025 •
  • •

Real-World Clinical Characteristics and Treatment Outcomes in PNH Patients Prescribed Pegcetacoplan: Insights of Complement Inhibitor-Experienced and -Naïve Patients Across Europe, the United States and Canada  

Jens Panse , Koo Wilson, Brianne Kerr, Sam Williamson, Susanna Libby, Yasmin Taylor, Peter Hillmen, David Dingli

Publication
  • ASH •
  • 7 December, 2025 •
  • •

Early Results From the Ongoing Pegcetacoplan Silo of the International Paroxysmal Nocturnal Hemoglobinuria Interest Group Registry 

Carlos de Castro, Peter Hillmen, Peter Blandino, David Araten

Publication
  • ASH •
  • 6 December, 2025 •
  • •

Optimizing PNH Treatment with the Complement Inhibitor Pegcetacoplan: A Case Report 

Edo Schaefer, Maya Siegel, Peter Blandino, Peter Hillmen

Sign up for alerts